A sensitive and specific high-pressure liquid chromatographic assay was developed to characterize the plasma elimination and urinary excretion of mitomycin C in humans. Extraction of mitomycin C and an internal standard, porfiromycin, from plasma by chromatography over a non-ionic resin, Porapak Q, yields high recovery of both compounds and facilitates measurement of as little as 5 ng mitomycin C by reversed-phase high-pressure liquid chromatography. The assay was used to characterize the plasma elimination of mitomycin C in rabbits and was shown to be applicable to the characterization of the pharmacokinetics of mitomycin C in humans receiving as little as 8 mg/m2.
Objectives (i) To assess the efficacy and tolerability of tropisetron when used for acute and delayed cisplatin‐induced emesis. (ii) To investigate whether dexamethasone added to tropisetron improves the control of emesis for patients who do not achieve a complete response to tropisetron alone. (iii) To assess sex of the patient and alcohol intake as prognostic factors for nausea and vomiting. Design A prospective open label phase II trial over one or two cycles of chemotherapy. Data collection was based on observed response and patients’ self‐reporting. Setting Twenty Australian tertiary care hospitals in 1994. Patients 102 male and female patients from 18 to 75 years with histologically confirmed malignancy receiving their first chemotherapy containing ≥50 mg/m2 cisplatin. Intervention In Cycle 1 tropisetron 5 mg was given intravenously before chemotherapy on Day 1, then 5 mg orally before breakfast on Days 2 to 6. In Cycle 2, dexamethasone 20 mg intravenously on Day 1, then 8 mg orally on Days 2 to 6 could be added to tropisetron if a complete antiemetic response had not been achieved in Cycle 1. Main outcome measures Number of vomiting episodes and severity of nausea for 6 days after chemotherapy; severity of side effects; patient satisfaction with chemotherapy treatment; oestradiol levels in women; and past alcohol consumption in men and women. Results (i) The complete response rate (CR) for acute emesis in Cycle 1 was 64% (95% confidence interval [CI], 54%–72%), with 84% (95% CI, 76%–90%) having ≤2 vomits. The CR for delayed emesis was 24% (95% CI, 17%–32%). The CR for acute nausea was 56% (95% CI, 47%–66%), with 97% (95% CI, 91%–99%) having ≤2 nausea episodes. The CR for delayed nausea was 21% (95% CI, 14%–30%). Seventy‐one patients received Cycle 2. The main side effects were headache (20 patients) and constipation (16 patients). The control of acute emesis was rated as “good” or “very good” by 68% of investigators; 85% rated the tolerability of treatment as “good” or “very good”. Treatment was rated as “very satisfactory” or “satisfactory” by 52% of patients. (ii) The CR for acute emesis with dexamethasone added was 78% (95% CI, 64%–88%). (iii) Women with lower oestradiol levels had better control of emesis, although this difference was not statistically significant. Chronic alcohol intake and binge drinking were strongly associated with a complete acute antiemetic response. Conclusions Tropisetron was effective for acute cisplatin‐induced emesis; adding dexamethasone enhanced this response. Both single and combined therapy had less effect on delayed emesis. The impact of alcohol on control of emesis is a chronic rather than acute phenomenon which requires prospective testing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.